28.51 USD
▼-5.49-16.15%
盘后 27.94 -2.00%
2026-08-05
市值
$1.76B
市盈率
—
EPS
—
股息率
—
52 周区间
—
成交量
18.37K
Beta
2.64
目标价
—
价格走势
公司简介
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that le...